Brought to you by 
Tekmira, Roche sign siRNA collaboration; terminated; now taken over by Arrowhead
02 Nov 2011
Executive Summary
After signing an initial preliminary agreement one year ago, Canadian RNAi firm Tekmira Pharmaceuticals and Roche have finalized a deal to develop the Big Pharma's first two siRNA candidates using Tekmira's Stable Nucleic Acid-Lipid Particle (SNALP) delivery system.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tekmira, Roche sign siRNA collaboration; terminated; now taken over by Arrowhead
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice